Renaissance Technologies’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Renaissance Technologies’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18,890	Closed	-$406K	–	4114
2024 Q1	$406K	Buy	18,890 +7,630	+68%	+$50.6K	﹤0.01%	2957
2023 Q4	$41K	Buy	11,260 +1,000	+10%	+$3.94K	﹤0.01%	3490
2023 Q3	$40K	Buy	+10,260	New	+$40.1K	﹤0.01%	3437
2023 Q2	–	Sell	-7,920	Closed	-$24K	–	4419
2023 Q1	$24K	Sell	7,920 -4,620	-37%	-$17.1K	﹤0.01%	3802
2022 Q4	$63K	Sell	12,540 -13,330	-52%	-$51K	﹤0.01%	3752
2022 Q3	$168K	Sell	25,870 -13,003	-33%	-$113K	﹤0.01%	3438
2022 Q2	$283K	Buy	38,873 +4,823	+14%	+$43.9K	﹤0.01%	3485
2022 Q1	$502K	Buy	34,050 +16,940	+99%	+$431K	﹤0.01%	3191
2021 Q4	$821K	Buy	17,110 +16,020	+1,470%	+$1.68M	﹤0.01%	2790
2021 Q3	$159K	Buy	+1,090	New	+$141K	﹤0.01%	3252

Renaissance Technologies's LABP Position: Q2 2024 in Review

Renaissance Technologies sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 18,890 shares — an estimated $406K sold.

Renaissance Technologies first reported a position in LABP in Q3 2021 and held it in 10 quarters. The position peaked at $821K in Q4 2021. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.

Renaissance Technologies reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Renaissance Technologies sold 18,890 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $406K.
Renaissance Technologies first reported a position in Landos Biopharma, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
Renaissance Technologies's Landos Biopharma, Inc. Common Stock position peaked at $821K in Q4 2021.
0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.